Grizzly alleges governance failures through Näder's conflicted extraction of over €600 million in withdrawals against only €340 million in after-tax earnings from 2010–2022, fraud and deception through what German accounting experts called 'impermissible' R&D capitalization (€246.6 million versus Össur's €21.8 million) and misleading 'Underlying Core EBITDA' metrics, and structural overvaluation at approximately 42x trailing earnings versus a peer-implied fair value of ~€30 per share.

Grizzly's analysis draws on Näder Holding GmbH & Co. KG's 2024 annual report (showing equity of -€77 million and loan nominal of €1,222.8 million), the Ottobock IPO prospectus filed September 2025, BaFin filings as of March 31, 2026, export databases (volza.com), Unternehmensregister filings, peer comparisons to Össur/Embla Medical, and consultation with German accounting and audit experts who called the accounting practices impermissible.

The PIK loan matures on March 31, 2030, at which point Grizzly estimates a repayment obligation of approximately €2.36 billion, and a margin call is expected if Ottobock's share price falls below approximately €38.58, representing a current loan-to-value ratio of 36.1% against a trigger threshold of approximately 55%.

Not Present: Thesis-Only

PIK Loan Pledges All Shares, Threatens Takeover

Näder entered a €1,100 million PIK loan in March 2024 to buy back 20% of Ottobock from EQT before the IPO. Per Näder Holding's 2024 annual report (p. 17), all of Näder's Ottobock shares are pledged as collateral, stated in German: 'die Anteile an der Ottobock SE & Co. KGaA verpfändet.' The IPO prospectus (filed September 2025, p. 34) shows the loan was restructured: principal reduced to €1.02 billion and maturity extended to March 31, 2030, with shares still fully pledged. Grizzly estimates that at the implied ~15% p.a. interest rate, Näder will owe approximately €2.36 billion at maturity, with lenders including Carlyle Global Credit, KKR, Hayfin Capital Management, and Macquarie Capital Principal Finance. Carlyle has recent precedent of assuming control via debt-for-equity swaps, as it did with Keter in 2024 after a €1.2 billion loan default.

Näder Extracted More Than Ottobock Earned for Over a Decade

WirtschaftsWoche reported payments to Näder of €600 million against only €340 million in after-tax earnings for Ottobock from 2010 to 2022. Grizzly infers from the decline in Näder Holding's equity that Näder burned approximately €45 million annually on average from 2011 to 2024 across his other operations, private consumption, and interest payments. Näder's documented personal expenditures include two luxury superyachts (Pink Gin VI and Pink Shadow), a Bombardier Global 7500 private jet (purchase cost $81 million, $4.4 million annually), art, and real estate. Union representative Oliver Mizera publicly stated Ottobock's leadership is 'partially exploiting' the company. Grizzly estimates that with approximately €423 million in equity remaining today against ~€200 million in annual interest plus private consumption, Näder Holding faces negative equity again in approximately two years.

Russia Business Hidden, Estimated at 35.1% of Net Income

Ottobock's Russian revenue share grew from 5.0% in 2023 to 6.8% in 2024 to 8.8% in H1 2025, even as the company announced it was reducing its Russian presence from seven to four locations, yet Ottobock discontinued regional sales reporting for 2025 by subsuming Russian figures into the broader 'EMEA' segment. Grizzly estimates that Russia accounted for €56.8 million of €184.0 million in total revenue growth from 2023 to 2025 (31% of total growth), and that applying 2023 profitability ratios yields a Russian profit share of €21.1 million out of €60.0 million in total group profit, or 35.1%. Competitor Össur (now Embla Medical) suspended its Russia business entirely in 2022. Business Insider (April 2025) published an investigative report showing Ottobock prosthetics appearing in Russian media and propaganda channels; Wirtschaftswoche (September 2025) reported Ottobock exported sanctioned goods into Russia and maintained business relationships with at least one Russian military hospital. The 19th EU Sanctions Package (October 2025) and Russian countersanctions have significantly restricted repatriation of cash from Russia, meaning the estimated €12–21 million annual profit from Russia may be effectively trapped.

R&D Capitalization 9.6x Higher Than Comparable Peer

Grizzly compares Ottobock's R&D accounting to Össur/Embla Medical, its closest industry peer. Ottobock records €246.6 million in 'Development Costs' carrying amount on its balance sheet, representing 12.0% of total assets, versus Össur's $21.8 million in 'Patents & Development Costs,' representing only 1.25% of total assets. Annual R&D spending levels are comparable: Ottobock spent €72.7 million (3.5% of asset value) versus Össur's €45.9 million (2.6% of asset value), and neither company dramatically changed R&D funding in recent years. Grizzly states that Ottobock's capitalized development costs on the balance sheet are 9.6 times higher relative to total assets than Össur's, a disparity it believes 'is too big to be explained by product portfolio and development efficiency alone,' suggesting over-aggressive capitalization to artificially inflate profit margins. German accounting and audit experts consulted by Grizzly called the accounting practices impermissible.

Misleading Adjusted Metrics Mask 5.3% True GAAP Margin

Ottobock's primary reported metric is 'Underlying Core EBITDA,' which excludes non-core business units, defined as any subsidiary or unit for which management has made a resolution to divest or discontinue within 18 months, even if no buyer exists. Grizzly characterizes this as 'genuine cherry-picking,' noting that management can exclude any poorly performing segment simply by formally deciding to offer it for sale. As a result, Ottobock presents 'Underlying Core EBITDA margins' of 26.0% to investors, while actual GAAP IFRS net margins are only 5.3%. Ottobock also uses depreciation periods of 10–25 years for technical equipment and machines versus Össur's 3–15 years, with the 25-year maximum allowing large equipment units to remain on the balance sheet far longer. Ottobock's earnings grew 196.5% from 2024 to 2025, but Grizzly notes this growth is not reflected in free cash flow, and Q1 2026 results showed earnings grew only 9.3% year-over-year, while Embla Medical showed much stronger growth.